Effect of phylloquinone supplementation on glucose homeostasis in humans

Kumar, Rajiv; Binkley, Neil; Vella, Adrian

doi:10.3945/ajcn.2010.30108

Cited by 63 publications

(55 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of effect on glucose metabolism is consistent with findings from two randomized trials of vitamin K1 supplementation, a treatment that substantially lowers ucOC levels without reducing bone turnover. These trials reported no effect on fasting glucose or insulin resistance over 1 year (34) and 3 years. (12) The small differences in weight change that we observed with alendronate and denosumab are consistent in direction with findings from rodent models.…”

Section: Discussionmentioning

confidence: 99%

“…It is possible that only very low or very high levels of ucOC have an appreciable effect on glucose metabolism, although substantial lowering of ucOC in postmenopausal women by vitamin K1 did not alter fasting glucose or insulin resistance. (34) Future research might focus on effects in patients with the largest changes in ucOC in response to osteoporosis therapies. Additionally, the trial participants were postmenopausal women, whereas the rodent studies were conducted in male and female mice with normal gonadal function.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials

Schwartz

Schafer

Grey

et al. 2013

Journal of Bone and Mineral Research

116

View full text Add to dashboard Cite

In rodent models, undercarboxylated osteocalcin (ucOC) acts as a hormone that promotes insulin sensitivity and secretion. If ucOC plays a similar role in humans, then antiresorptive therapies, which reduce ucOC levels, may increase the risk of insulin resistance and diabetes. We tested whether antiresorptive therapies result in higher fasting glucose, increased weight, or greater diabetes incidence in post hoc analyses of three randomized, placebo-controlled trials in postmenopausal women: Fracture Intervention Trial (FIT) (N ¼ 6151) of alendronate (4 years

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials

Schwartz

Schafer

Grey

et al. 2013

Journal of Bone and Mineral Research

116

View full text Add to dashboard Cite

show abstract

“…Epidemiological studies have specifically examined the association of metabolic parameters with serum undercarboxylated osteocalcin levels, the hormonally active form of osteocalcin, but the results are not uniform and were not demonstrated in all studies (36)(37)(38)(39)(40). An important limitation of these studies is the lack of homogeneity and established specificity of commercially available assays to detect the undercarboxylated osteocalcin isoform (41-43).…”

Section: Human Studies Involving Undercarboxylated Osteocalcinmentioning

confidence: 99%

Osteocalcin, energy and glucose metabolism

Zanatta

Boguszewski

Borba

et al. 2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Osteocalcin is a bone matrix protein that has been associated with several hormonal actions on energy and glucose metabolism. Animal and experimental models have shown that osteocalcin is released into the bloodstream and exerts biological effects on pancreatic beta cells and adipose tissue. Undercarboxylated osteocalcin is the hormonally active isoform and stimulates insulin secretion and enhances insulin sensitivity in adipose tissue and muscle. Insulin and leptin, in turn, act on bone tissue, modulating the osteocalcin secretion, in a traditional feedback mechanism that places the skeleton as a true endocrine organ. Further studies are required to elucidate the role of osteocalcin in the regulation of glucose and energy metabolism in humans and its potential therapeutic implications in diabetes, obesity and metabolic syndrome. Arq Bras Endocrinol Metab. 2014;58(5):444-51 Keywords Osteocalcin; undercarboxylated osteocalcin; metabolic syndrome; glucose; energy metabolism; diabetes; obesity; leptin; insulin; adiponectin RESUMO A osteocalcina é uma proteína da matriz óssea que tem sido implicada com várias ações hormonais relacionadas à homeostase de glicose e ao metabolismo energéti-co. Modelos animais e experimentais têm demonstrado que a osteocalcina é liberada do osso para a circulação sanguínea e age nas células betapancreáticas e no tecido adiposo. A osteocalcina decarboxilada é a isoforma hormonalmente ativa e estimula a secreção e sensibilidade à insulina no tecido adiposo e muscular. A insulina e a leptina, por sua vez, atuam no tecido ósseo modulando a secreção da osteocalcina, formando uma alça de retroalimentação tradicional em que o esqueleto torna-se um órgão endócrino. Novos estudos ainda são necessários para elucidar o papel da osteocalcina na regulação glicêmica e no metabolismo energético em humanos, com potenciais implicações terapêuticas no tratamento de diabetes, obesidade e síndrome metabólica. Arq Bras Endocrinol Metab. 2014;58(5):444-51 Descritores

show abstract

“…Subsequent clinical experiments tried to look at this contradiction in humans, but the results so far are inconsistent and equivocal. To mention few of these: Kumar et al, for example, found that phylloquinone administration in post menopausal women was not associated with changes in insulin secretion and action despite reductions in concentrations of under carboxylated osteocalcin (13). In another clinical study (14) both under carboxylated and carboxylated forms of osteocalcin were associated with different aspects of improved glucose tolerance -enhanced beta-cell function and improved insulin sensitivity, respectively.…”

Section: Discussionmentioning

confidence: 99%

Effects of vitamin K on liver steatosis and pancreatic lipomatosis in experimental model of metabolic syndrome

Kitanova¹,

Popov²,

Gancheva³

et al. 2016

TJS

View full text Add to dashboard Cite

PURPOSE:Recently new roles for vitamin K, different from that in coagulation, have been proposed, including prevention of cardiometabolic diseases. It was the aim of the present work to evaluate the impact of vitamin K treatment on the changes in liver and pancreas of rats with experimentally induced metabolic syndrome. METHODS: Four groups of rats were used, as follows: one control group fed regular rat chow; one group fed high fat, high fructose (HFHF) diet for 12 weeks to induce a metabolic syndrome (MS) and two groups with MS treated with vitamin K1 and K2 respectively. At the end of the experiment, liver tissue and pancreatic were dissected out for morphological examination. RESULTS: All groups of rats fed HFHF diet expressed liver histological changes consistent with steatosis. These alterations were more pronounced in the groups treated with vitamin K2 and K1. The pancreatic tissue of the HFHF fed animals showed similar degree of lipomatosis irrespective of treatment. CONCLUSIONS:In rats with diet-induced MS, treatment with vitamin K1 and K2 did not produce the expected morphological evidence of improvement, even tended to aggravate the liver changes. These results disagreed with other effects of vitamin K that were established.

show abstract

Effect of phylloquinone supplementation on glucose homeostasis in humans

Cited by 63 publications

References 27 publications

Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials

Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials

Osteocalcin, energy and glucose metabolism

Effects of vitamin K on liver steatosis and pancreatic lipomatosis in experimental model of metabolic syndrome

Contact Info

Product

Resources

About